Bristol's BARACLUDE Tablet for Chronic Hepatitis B Virus Infection Granted Priority Review by Government.
Discovered by Bristol-Myers Squibb, BARACLUDE (entecavil) is an oral nucleoside analogue that selectivity inhibits HBV polymerase. In Japan, it is estimated that more than 10 million people develop chronic HBV infection and about 35,000 people die from liver cancer triggered by HBV infection every year.
Bristol Pharmaceutical has filed applications for BARACLUDE, which was initially approved in the US in March 2005, on August 31.
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Nov 14, 2005|
|Previous Article:||Yokohama Rubber Announces Auto Parts Manufacturing and Conveyor Belt Joint Ventures in China.|
|Next Article:||Toyota Registers First Hybrid Vehicles in China.|